-- Emergent BioSolutions (EBS) 周二宣布，已与 Substipharm Biologics 签署一项价值 3450 万美元的协议，为其位于马萨诸塞州坎顿的工厂提供日本脑炎疫苗原料药生产支持。 根据协议，Emergent 表示，在获得美国食品药品监督管理局 (FDA) 的监管批准后，该公司将成为该疫苗在美国的独家分销商。 根据一项主生产服务协议，Emergent 表示将负责该疫苗的运营和监管检查准备工作。 Emergent 股价周二上涨 1.6%。
Price: $8.16, Change: $+0.13, Percent Change: +1.62%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Visa posted excellent Mar-Q results with adj. EPS of $3.31 vs. $2.76 a year ago, beating consensus by $0.21. Revenue of $11.2B rose 17% Y/Y, beating consensus by 4% and marking the strongest growth since 2022. We view this as an excellent result, as concerns surrounding AI disruption or geopolitical uncertainty did not manifest in Visa's performance. Adjusted operating margin held firm at 68.0%, a good result given prior guidance indicated likely margin compression. Strong performance was broad based with data processing revenue up 18% to $5.5B and other revenue surging 41% to $1.3B, reflecting successful expansion in value-added services. Cross-border volume excluding intra-Europe advanced 11% on a constant currency (CC) basis while payments volume grew 9%. Geographic strength was led by LAC (+14% CC), CEMEA (+13% CC), and Europe (+11% CC), with encouraging acceleration in the U.S. to 8%. We applaud the board's authorization of a new $20B multi-year share repurchase program given Visa's muted valuation.
Thomson Reuters (TRI.TO, TRI), was last seen down 3% in after-hours Nasdaq trading, said Tuesday that shareholders approved a plan of arrangement to implement the company's proposed return of capital and share consolidation transactions.The company said a final report on voting results will be filed with Canadian securities regulators and furnished to the U.S. Securities and Exchange Commission.The return of capital and share consolidation transactions consist of a special cash distribution of US$605 million, or approximately US$1.36 per share.The plan of arrangement for the return of capital and share consolidation transactions is subject to final approval by the Ontario Superior Court of Justice as well as the Toronto Stock Exchange and the Nasdaq. The court hearing for a final order to approve the plan of arrangement is scheduled on April 29.The company's shares were down US$2.66 to US$87.23 in after-hours after closing up C$1.56 at C$123.04 on TSX.
Northern Oil and Gas (NOG) Q1 adjusted earnings late Tuesday of $0.74 per diluted share, down from $1.33 a year earlier.Analysts polled by FactSet expected $0.68.Revenue for the quarter ended March 31 was $5 million, compared with $602.1 million a year earlier.Analysts surveyed by FactSet expected $511.4 million.